Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Recommendation of “Buy” from Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX) has received a consensus recommendation of “Buy” from the six analysts that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $9.50.

Several research firms have weighed in on QNCX. D. Boral Capital reiterated a “buy” rating and issued a $12.00 price target on shares of Quince Therapeutics in a research report on Thursday, January 2nd. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 22nd. Brookline Capital Management assumed coverage on Quince Therapeutics in a report on Wednesday, December 18th. They set a “buy” rating and a $9.00 price target for the company. Maxim Group assumed coverage on Quince Therapeutics in a research note on Thursday, November 7th. They issued a “buy” rating and a $6.00 price objective on the stock. Finally, Rodman & Renshaw started coverage on Quince Therapeutics in a research note on Tuesday, October 29th. They set a “buy” rating and a $11.00 price objective for the company.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC lifted its holdings in Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 339,125 shares of the company’s stock after purchasing an additional 66,170 shares during the quarter. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 as of its most recent SEC filing. Institutional investors and hedge funds own 30.75% of the company’s stock.

Quince Therapeutics Stock Performance

Shares of QNCX stock opened at $1.61 on Monday. The firm has a market capitalization of $70.84 million, a PE ratio of -1.30 and a beta of 0.64. The company has a 50 day moving average price of $1.84 and a 200-day moving average price of $1.25. Quince Therapeutics has a 52 week low of $0.51 and a 52 week high of $2.45. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.